REFERENCES:


F.S. Luppino et al., Overweight, Obesity, and Depression, Arch Gen Psychiatry, 67(3): 2010, P 220-229.

Fast Facts: Obesity, ‘Pharmacological and surgical treatments; Health Press Ltd. Chapter-9; 2009; 101-120.

Faucette et al., Bupropion Hydroxylation as a CYP2b6 Catalytic Marker, Drug Metabolism and Disposition, 2000, Vol. 28, (10), P 1222–30.


Gerold Mosher et al., Complexation-Cyclodextrins, In: Encyclopedia of Pharmaceuticals; Informa Healthcare USA, 2007; P-671-696.


John B. Dixon et al., Depression in Association with Severe Obesity, Archives of Internal Medicine 2003; 163:P2058-65.


Loyd VJ. Popovich NG. Ansel H.C., Pharmaceutical dosage form and Drag Delv system, lippincott Williams and wilkins 2007.3rd ed. p.234

Marsha D. Marcus, et al., Obesity: Is it a Mental Disorder, InternationaJurnal of Eting Disorders, 2009, 42:8 739–753


Reiland and Lipari, Flavor and Flavor Modifiers, In: Encyclopedia of Pharmaceutics; Informa Healthcare USA, 2007; P-1763-1772.


Samantha Scholtz, John F. Morgan, Obesity and psychiatry , Volume 8, Issue 6, June 2009; 198-202.


Szejtli and Szente, Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins.-European journal of pharmaceutics and biopharmaceutics 61 (2005), P 115 – 125.

T Florence and D Attwood, The solubility of drugs, In; Physicieschemical Principals of Pharmacy, Pharmaceutical Press UK, 2006; P140-177.


W. M. Saltzman, Introdauction Chapter, In: Engeniering Principals for drug tharepy, Oxford Univeristy Prress, Inc. 2001; P-03-08.

